Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass387.47 g/mol
3D model (JSmol)
<templatestyles src="Nobold/styles.css"/> ☒N☑Y (what is this?)<templatestyles src="Nobold/styles.css"/>  (verify)

WikiDoc Resources for Trimebutine


Most recent articles on Trimebutine

Most cited articles on Trimebutine

Review articles on Trimebutine

Articles on Trimebutine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Trimebutine

Images of Trimebutine

Photos of Trimebutine

Podcasts & MP3s on Trimebutine

Videos on Trimebutine

Evidence Based Medicine

Cochrane Collaboration on Trimebutine

Bandolier on Trimebutine

TRIP on Trimebutine

Clinical Trials

Ongoing Trials on Trimebutine at Clinical

Trial results on Trimebutine

Clinical Trials on Trimebutine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Trimebutine

NICE Guidance on Trimebutine


FDA on Trimebutine

CDC on Trimebutine


Books on Trimebutine


Trimebutine in the news

Be alerted to news on Trimebutine

News trends on Trimebutine


Blogs on Trimebutine


Definitions of Trimebutine

Patient Resources / Community

Patient resources on Trimebutine

Discussion groups on Trimebutine

Patient Handouts on Trimebutine

Directions to Hospitals Treating Trimebutine

Risk calculators and risk factors for Trimebutine

Healthcare Provider Resources

Symptoms of Trimebutine

Causes & Risk Factors for Trimebutine

Diagnostic studies for Trimebutine

Treatment of Trimebutine

Continuing Medical Education (CME)

CME Programs on Trimebutine


Trimebutine en Espanol

Trimebutine en Francais


Trimebutine in the Marketplace

Patents on Trimebutine

Experimental / Informatics

List of terms related to Trimebutine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.[1] The maleic acid salt of trimebutine is marketed under the trademark of Debridat, Recutin, Polybutin,[2] or Modulon for treatment of irritable bowel syndrome and other gastrointestinal disorders. The major product from drug metabolism of trimebutine in human beings is nortrimebutine,[3] which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract.[4] Both Trimebutine and its metabolite are commercially available.

See also


  1. Kaneto H, Takahashi M, Watanabe J. The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. Journal of Pharmacobiodynamics. 1990 Jul;13(7):448-53. PMID 1963196
  2. Ok Hwa Jhee, Yun Sik Lee, Leslie M. Shaw, Yong Cheol Jeon, Min Ho Lee, Seung Hoon Lee and Ju Seop Kang The Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC–MS/MS method. Clinica Chimica Acta. 2007 Jan;375(1-2):69-75. PMID 16854404
  3. F.J. Roman, S. Lanet, J. Hamon, G. Brunelle, A. Maurin, P. Champeroux, S. Richard, N. Alessandri, and M. Gola Pharmacological Properties of Trimebutine and N-Monodesmethyltrimebutine. The Journal of Pharmacology and Experimental Therapeutics 1999;289:1391–1397. PMID 10336531
  4. Hiyama, T.; Yoshihara, M.; Tanaka, S.; Haruma, K.; Chayama, K. (Apr 2009). "Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract" (PDF). J Gastroenterol Hepatol. 24 (4): 537–46. doi:10.1111/j.1440-1746.2009.05780.x. PMID 19220673.<templatestyles src="Module:Citation/CS1/styles.css"></templatestyles>

Template:Drugs for functional gastrointestinal disorders}